Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupDermatologic OncologySarcomasDiseaseKaposi SarcomaSubgroupICD10C46.1MeSHSarcoma, KaposiSequenceChemotherapyChemo-substanceBortezomibDoxorubicin pegylated liposomalEtoposideGemcitabineIpilimumabLenalidomideNivolumabPomalidomideVinorelbineChemo-substanceBortezomibDoxorubicin pegylated liposomalEtoposideGemcitabineIpilimumabLenalidomideNivolumabPomalidomideVinorelbineChemo-substanceBortezomibDoxorubicin pegylated liposomalEtoposideGemcitabineIpilimumabLenalidomideNivolumabPomalidomideVinorelbineChemo-substanceBortezomibDoxorubicin pegylated liposomalEtoposideGemcitabineIpilimumabLenalidomideNivolumabPomalidomideVinorelbineNo. Substances12 RadiotherapySupportive therapySupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronPyridoxineSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronPyridoxineSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronPyridoxineSupportive substanceAciclovirBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneGranisetronPyridoxineNo. Substances123Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineSecond lineseveral possibleTherapy phaseTherapy intentionpalliativeRisksAlopeciaAnemia Hb below 8g/dlAnorexiaArthalgiaCardiotoxicityColitisConstipationDiarrheaDyspneaEdemaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHeadacheHyponatremiaHypophysitisHypothyroidismIncrease AminotransferasesIncrease in lipaseInfectionsNephritisNeuropathyNeutropeniaPneumoniaPruritusPyrexiaRashRenal FailureThrombocytopenia below 50 000/µl only studiesPublicationAuthorBusakhala NWCianfrocca MHosseinipour MCNasti GPolizzotto MNPourcher VReid EGZer ADiseaseKaposi Sarkom, Erstlinie, ECOG 0-2Kaposi Sarkom, HIV-assoziiert, Erstlinie, ECOG 0-2Kaposi Sarkom, HIV-assoziiert, rezidiviert oder therapierefraktär, ECOG 0-3Kaposi Sarkom, HIV-assoziiert, rezidiviert oder therapierefraktär, unter antiretroviraler TherapieKaposi Sarkom, mild-moderat, HIV-assoziiert, ErstlinieKaposi Sarkom, mindestens 1 VortherapieKaposi Sarkom, rezidiviert oder therapierefraktärOriginAssistance Publique-Hopitaux de Paris, Paris, France, ANRS 154 Lenakap TrialCentro di Riferimento Oncologico, Aviano, ItalyDivision of Oncology, Rambam Health Care Campus, HaifaMakerere College of Health Sciences, Kampala, UgandaNational Cancer Institute, Bethesda, USANorthwestern University, Chicago ILUniversity of California, San Diego Moores Cancer Center, AMC-063 trialUniversity of North Carolina School of Medicine, Chapel Hill, A5264/AMC-067 trialProtocols in Revision 8 protocols foundProtocols under revision.Bortezomib 1.6, Kaposi's Sarcoma (PID2028 V1.0)Etoposide 50, Kaposi's Sarcoma (PID2032 V1.0)Gemcitabine 1000, Kaposi's Sarcoma (PID2033 V1.0)Lenalidomide 25, Kaposi's Sarcoma (PID2029 V1.0)Nivolumab 240 / Ipilimumab 1, Kaposi Sarcoma (PID2160 V1.1)Doxorubicin Pegylated Liposomal 20, Kaposi Sarcoma (PID1201 V1.1)Pomalidomide 4, Kaposi's Sarcoma (PID2030 V1.0)Vinorelbine 30, Kaposi's Sarcoma (PID2031 V1.0)
